查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2028 年的體內毒理學市場預測——按產品、實驗室、研究類型、毒性終點、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1273269

到 2028 年的體內毒理學市場預測——按產品、實驗室、研究類型、毒性終點、最終用戶和地區進行的全球分析

In Vivo Toxicology Market Forecasts to 2028 - Global Analysis By Product, Testing Facility, Test Type, Toxicity End Point, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC，全球體內毒理學市場規模將在 2022 年和 2028 年分別達到 55.6 億美元和 76 億美元，在預測期內以 5.5% 的複合年增長率增長。預計達到7000萬美元。

生物毒理學研究各種藥物對生物體（通常是動物）的毒性。 這與使用計算機模型和細胞係等非生命技術的體外毒理學相反。 此類研究調查化學品和藥物如何影響活體動物的行為和健康。 這些數據將用於製造有助於預防或治療某些人類疾病（例如癌症和阿爾茨海默病）的重要藥物。

根據美國疾病控制和預防中心 (CDC) 的數據，到 2021 年，美國將有大約 1820 萬 20 歲及以上的成年人患有冠狀動脈疾病 (CAD)。 心髒病是美國人死亡的主要原因。

市場動態：

驅動程序

原始體內毒性試驗

隨著體外和計算機毒性測試等替代方法的出現，一些毒性研究現在正在實驗室中進行。 但有些試驗只能在體內進行，如對兒童的致癌性、致畸性、生殖毒性、致突變性、神經毒性等發育毒性。 對藥物致癌毒性試驗的日益重視有望促進體內毒性試驗動物模型的引入。 據癌症研究所稱，目前正在進行長期的囓齒動物致癌性研究，以評估藥物對人類的致癌風險，這正在推動市場。

約束

動物試驗的替代方法

預計在沒有動物試驗的情況下使用體外模型進行產品開發會限制體內毒理學行業的發展。 這些模型在毒性研究中被廣泛接受，例如人類幹細胞、藥物、細胞培養模型和高通量測試。 此外，替代毒性測試方法的使用增加可能會減少對動物模型的需求並阻礙市場。

機會

對人源化動物模型的需求不斷增長

人性化動物模型是進行臨床前研究以更多地了解人類生物學的有用工具。 該模型是通過將人類細胞和組織移植到動物體內並表達人類蛋白質而創建的。 人源化小鼠越來越多地用作癌症、傳染病、HIV/AIDS、再生醫學和肝炎的研究模型。 越來越重視對人類特異性感染、治療和疾病的研究，以及對發現藥物對人類的真正影響的日益增長的需求，為市場增長提供了廣泛的機會。

威脅

動物測試法規和法律

動物保護和福利規章制度的實施導致動物因各種原因受到限制和禁止。 過去五年，許多國家禁止在化妝品中使用動物成分。 此外，美國國立衛生研究院 (NIH) 贊助的研究機構必須遵循公共衛生服務 (PHS) 政策和實驗室動物護理研究所 (ILAR) 實驗動物護理和使用指南。我們尋求。 研究機構尋求國際實驗動物護理評估和認證協會 (AAALAC) 的認證，但這阻礙了市場增長。

COVID-19 的影響：

人們越來越關注 COVID-19 疫苗的開發，預計將為擴大體內毒理學市場創造有利可圖的機會。 據世界衛生組織稱，目前全球有 20 種疫苗正在研發中，一些處於臨床前階段，另一些已經在進行動物試驗。 此外，在 SARS-CoV-2 複製中以小鼠模型為首的 COVID-19 研究中動物模型的有效利用有望推動市場擴張。 儘管大流行帶來了前景，但由於動物模型生產商無法滿足不斷增長的需求，現有供應有限。

慢性期預計在預測期內最大。

由於毒性研究是在至少一種囓齒動物和一種非囓齒動物物種中進行的，因此假設慢性期部分將有良好的生長。 測試物質給藥超過 90 天，並定期檢查動物。 慢性毒性研究提供了有關受試物質對動物的長期影響的信息，可以推斷出受試物質對人體的安全性。 因此，用於長期治療的藥物，如化學治療劑、抗癌劑、抗驚厥劑、抗高血壓劑和抗關節炎劑，需要進行長期毒性研究，從而推動該領域的擴展。

預計免疫毒性部分在預測期內的複合年增長率最高

由於過量服用藥物、生物製劑和接觸化學品會對免疫系統活動產生不利影響，預計在預測期內，免疫毒性將以最高複合年增長率增長。 接觸苯、石棉和鹵代芳烴會導致人體免疫抑制。

市場份額最高的地區

預計在預測期內，北美將佔據最高的市場份額。 這是因為對個性化藥物的高需求是北美市場的主要驅動力，包括美國和加拿大。 此外，加拿大干細胞研究部門的崛起，主要是由於與實施加拿大干細胞戰略和行動計劃相關的大量支出，也為北美市場做出了貢獻。

複合年增長率最高的地區：

由於其蓬勃發展的製藥和生物製藥行業以及不斷增加的研發投資，預計歐洲在預測期內的複合年增長率最高。 然而，由於早期階段的廣泛研究和開發推動了市場，預計該地區的體內毒理學技術活動將會增加。

主要發展：

2023 年 3 月，Charles River 發布了 Apollo(TM)，這是業界領先的基於雲的安全平台，用於實時毒性測試數據，該平台當前的功能包括安全評估，旨在支持客戶進行毒性測試。

2023 年 2 月，傑克遜實驗室與西北大學合作為臨床醫生開設心臟基因組學課程，西北大學幫助臨床醫生更好地識別有遺傳性心髒病風險的患者，使之成為可能。

2023 年 2 月，Charles River 宣布了一種基於 IgY 的新型 ELISA 試劑盒，用於檢測和定量殘留宿主細胞蛋白。 這種提高的靈敏度和特異性是由於使用了獨特的雞免疫球蛋白 y (IgY) 抗體。

這份報告提供了什麼

  • 區域和國家/地區細分市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議）。
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第2章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第3章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球體內毒理學市場：按產品分類

  • 消耗品
  • 設備
    • 動物模型
      • 大鼠模型
      • 小鼠模型
      • 其他動物模型
  • 其他產品

第 6 章全球體內毒理學市場：按實驗室分類

  • 合同測試設施
  • 內部測試設施

第 7 章全球體內毒理學市場：按測試類型

  • 亞急性
  • 急性
  • 亞慢性
  • 慢性
  • 其他測試類型

第 8 章全球體內毒理學市場：按毒性終點分類

  • 全身毒性
  • 致癌性
  • 遺傳毒性
  • 免疫毒性
  • 發育和生殖毒性 (DART)
  • 其他毒性終點

第 9 章全球體內毒理學市場：按最終用戶分類

  • 製藥和生物技術公司
  • 委託研究機構
  • 學術研究機構
  • 其他最終用戶

第 10 章全球體內毒理學市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第11章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • The Jackson Laboratory
  • Charles River Laboratories
  • Taconic Biosciences
  • Janvier Labs
  • Thermo Fisher Scientific
  • Waters Corporation
  • Danaher Corporation
  • Shimadzu Corporation
  • Agilent Technologies
  • PerkinElmer
  • Merck KGaA
  • GE Healthcare
  • genOway
  • Bio-Rad Laboratories
  • Crown Biosciences
  • Harbour BioMed
  • Bruker Corporation
  • TransCure bioServices
Product Code: SMRC22814

According to Stratistics MRC, the Global In Vivo Toxicology Market is accounted for $5.56 billion in 2022 and is expected to reach $7.67 billion by 2028 growing at a CAGR of 5.5% during the forecast period. Vivo toxicology is the study of the toxicity of various medications on a living organism, usually an animal. This is in contrast to in vitro toxicology, which uses non-living technologies like as computer models and cell lines. This type of testing investigates how chemicals and medications affect the behaviour and health of living animals. This data is used in the creation of critical drugs that can help prevent and treat specific human diseases such as cancer and Alzheimer's.

According to the Centers for Disease Control and Prevention (CDC), in 2021, around 18.2 million adults aged 20 and older had coronary artery disease (CAD) in the United States. Heart disease is the leading cause of death among people in the United States.

Market Dynamics:

Driver:

Unique In vivo toxicological tests

Several toxicological tests are now carried out in laboratories, thanks to the emergence of alternative methodologies such as in vitro and in silico toxicity testing. Certain assays, however, are only available in vivo, such as tests for carcinogenicity, developmental including teratogenicity in children and reproductive toxicity, mutagenicity, and neurotoxicity. The increased emphasis on drug carcinogenic toxicity studies is likely to drive the adoption of animal models for in vivo toxicology testing. According to the Cancer Research Institute long term rodent carcinogenicity studies are currently being investigated in order to assess the carcinogenic risk of medications in humans which are propelling the market.

Restraint:

Animal testing alternatives

In the non-animal product development, the use of in vitro models is projected to limit the growth of the in vivo toxicology industry. Such models have acquired widespread acceptance in toxicological testing for human stem cells, pharmaceuticals, cell culture models, and high-throughput testing. Furthermore, the growing use of alternative toxicological testing techniques is likely to reduce need for animal models thereby hindering the market.

Opportunity:

Increasing demand for humanised animal models

Humanised animal models are useful instruments for performing preclinical research to learn more about human biology. These models are created by engrafting human cells or tissues into animals, resulting in the expression of human proteins. Humanised mice are increasingly being employed as study models for cancer, infectious illnesses, HIV/AIDS, regenerative medicine, and hepatitis. The rising emphasis on investigating human-specific infections, cures, and diseases, as well as the necessity to discover the actual effects of medications on humans creating wide range of opportunities for the growth of the market.

Threat:

Animal research regulations and laws

The implementation of animal protection and welfare rules and regulations has resulted in restrictive practises and animal bans for a variety of reasons. Many countries have prohibited the use of animals in the cosmetics sector in the last five years. Furthermore, institutes sponsored by the National Institutes of Health (NIH) are expected to follow Public Health Service (PHS) policy and the Institute for Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals. Research institutes seek accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC), which halts the market growth.

COVID-19 Impact:

The increased focus on COVID-19 vaccine development is expected to create lucrative chances for the market expansion of in vivo toxicology. According to the WHO, 20 vaccines are now in development around the world, with some in the preclinical stage and others having already entered the animal trial phase. Furthermore, the effective use of animal models in COVID-19 research, notably mice models in SARS-CoV-2 replication, is projected to drive market expansion. Despite the prospects presented by the pandemic, existing supply is limited because to animal model producers inability to fulfil increasing demand.

The chronic segment is expected to be the largest during the forecast period

The chronic segment is estimated to have a lucrative growth, due to toxicity testing are performed on at least one rodent and one non-rodent species. The test substance is administered over a period of more than 90 days, and the animals are examined on a regular basis. A chronic toxicological research gives information regarding the long-term effects of a test chemical in animals, which may then be extrapolated to the test substance's safety in humans. As a result, medications used for long-term therapy, such as chemotherapeutic agents, anti-cancer, anti-convulsive, anti-hypertensive, and anti-arthritic therapies, necessitate long-term toxicity testing, driving sector expansion.

The Immunotoxicity segment is expected to have the highest CAGR during the forecast period

The Immunotoxicity segment is anticipated to witness the highest CAGR growth during the forecast period, due to the unfavourable effects on immune system activities produced by excessive medication exposure, biologics, or chemical compound exposure. Human immunosuppression may result from exposure to benzene, asbestos, and halogenated aromatic hydrocarbons.

Region with highest share:

North America is projected to hold the highest market share during the forecast period owing to the high demand for personalised pharmaceuticals is the primary driver of the North American market which includes the United States and Canada. Furthermore, the rise of the Canadian stem cell research sector, which is primarily driven by large-scale expenditures as a result of the implementation of the Canadian Stem Cell Strategy and Action Plan, is a contributing factor to the North America market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the region's thriving pharmaceutical and biopharmaceutical industries, as well as the increased investment in R&D. However, due to the extensive R&D in the early stages, which is projected to drive the market, the In Vivo Toxicology technique activities are likely to expand in this region

Key players in the market:

Some of the key players profiled in the In Vivo Toxicology Market include: The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Janvier Labs, Thermo Fisher Scientific, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Agilent Technologies, PerkinElmer, Merck KGaA, GE Healthcare, genOway, Bio-Rad Laboratories, Crown Biosciences, Harbour BioMed, Bruker Corporation and TransCure bioServices

Key Developments:

In March 2023, Charles River Launches Apollo™, an industry-leading, secure, cloud-based platform for real-time toxicology study data, the platform's current capabilities are designed to support clients with safety assessment and toxicology studies.

In Feb 2023, The Jackson Laboratory partners with northwestern to create cardiogenomics course for clinicians, with northwestern university will help clinicians better identify patients at risk for genetic cardiac disease.

In Feb 2023, Charles River Launches Novel IgY-based ELISA Kit for the detection and quantitation of residual host cell protein, this increase in sensitivity and specificity can be attributed to the unique chicken immunoglobulin y (IgY) antibodies utilized.

Products Covered:

  • Consumables
  • Instruments
  • Other Products

Testing Facilities Covered:

  • Outsourced Testing Facility
  • In-House Testing Facility

Test Types Covered:

  • Sub-Acute
  • Acute
  • Sub-Chronic
  • Chronic
  • Other Test Types

Toxicity End Points Covered:

  • Systemic Toxicity
  • Carcinogenicity
  • Genotoxicity
  • Immunotoxicity
  • Developmental & Reproductive Toxicity (DART)
  • Other Toxicity Endpoints

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Vivo Toxicology Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Instruments
    • 5.3.1 Animal Models
      • 5.3.1.1 Rat Models
      • 5.3.1.2 Mice Models
      • 5.3.1.3 Other Animal Models
  • 5.4 Other Products

6 Global In Vivo Toxicology Market, By Testing Facility

  • 6.1 Introduction
  • 6.2 Outsourced Testing Facility
  • 6.3 In-House Testing Facility

7 Global In Vivo Toxicology Market, By Test Type

  • 7.1 Introduction
  • 7.2 Sub-Acute
  • 7.3 Acute
  • 7.4 Sub-Chronic
  • 7.5 Chronic
  • 7.6 Other Test Types

8 Global In Vivo Toxicology Market, By Toxicity End Point

  • 8.1 Introduction
  • 8.2 Systemic Toxicity
  • 8.3 Carcinogenicity
  • 8.4 Genotoxicity
  • 8.5 Immunotoxicity
  • 8.6 Developmental & Reproductive Toxicity (DART)
  • 8.7 Other Toxicity Endpoints

9 Global In Vivo Toxicology Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Contract Research Organizations
  • 9.4 Academic & Research Institutes
  • 9.5 Other End Users

10 Global In Vivo Toxicology Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 The Jackson Laboratory
  • 12.2 Charles River Laboratories
  • 12.3 Taconic Biosciences
  • 12.4 Janvier Labs
  • 12.5 Thermo Fisher Scientific
  • 12.6 Waters Corporation
  • 12.7 Danaher Corporation
  • 12.8 Shimadzu Corporation
  • 12.9 Agilent Technologies
  • 12.10 PerkinElmer
  • 12.11 Merck KGaA
  • 12.12 GE Healthcare
  • 12.13 genOway
  • 12.14 Bio-Rad Laboratories
  • 12.15 Crown Biosciences
  • 12.16 Harbour BioMed
  • 12.17 Bruker Corporation
  • 12.18 TransCure bioServices

List of Tables

  • Table 1 Global In Vivo Toxicology Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global In Vivo Toxicology Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global In Vivo Toxicology Market Outlook, By Consumables (2020-2028) ($MN)
  • Table 4 Global In Vivo Toxicology Market Outlook, By Instruments (2020-2028) ($MN)
  • Table 5 Global In Vivo Toxicology Market Outlook, By Animal Models (2020-2028) ($MN)
  • Table 6 Global In Vivo Toxicology Market Outlook, By Rat Models (2020-2028) ($MN)
  • Table 7 Global In Vivo Toxicology Market Outlook, By Mice Models (2020-2028) ($MN)
  • Table 8 Global In Vivo Toxicology Market Outlook, By Other Animal Models (2020-2028) ($MN)
  • Table 9 Global In Vivo Toxicology Market Outlook, By Other Products (2020-2028) ($MN)
  • Table 10 Global In Vivo Toxicology Market Outlook, By Testing Facility (2020-2028) ($MN)
  • Table 10 Global In Vivo Toxicology Market Outlook, By Outsourced Testing Facility (2020-2028) ($MN)
  • Table 11 Global In Vivo Toxicology Market Outlook, By In-House Testing Facility (2020-2028) ($MN)
  • Table 12 Global In Vivo Toxicology Market Outlook, By Test Type (2020-2028) ($MN)
  • Table 14 Global In Vivo Toxicology Market Outlook, By Sub-Acute (2020-2028) ($MN)
  • Table 15 Global In Vivo Toxicology Market Outlook, By Acute (2020-2028) ($MN)
  • Table 16 Global In Vivo Toxicology Market Outlook, By Sub-Chronic (2020-2028) ($MN)
  • Table 17 Global In Vivo Toxicology Market Outlook, By Chronic (2020-2028) ($MN)
  • Table 18 Global In Vivo Toxicology Market Outlook, By Other Test Types (2020-2028) ($MN)
  • Table 19 Global In Vivo Toxicology Market Outlook, By Toxicity End Point (2020-2028) ($MN)
  • Table 20 Global In Vivo Toxicology Market Outlook, By Systemic Toxicity (2020-2028) ($MN)
  • Table 21 Global In Vivo Toxicology Market Outlook, By Carcinogenicity (2020-2028) ($MN)
  • Table 22 Global In Vivo Toxicology Market Outlook, By Genotoxicity (2020-2028) ($MN)
  • Table 23 Global In Vivo Toxicology Market Outlook, By Immunotoxicity (2020-2028) ($MN)
  • Table 24 Global In Vivo Toxicology Market Outlook, By Developmental & Reproductive Toxicity (DART) (2020-2028) ($MN)
  • Table 25 Global In Vivo Toxicology Market Outlook, By Other Toxicity Endpoints (2020-2028) ($MN)
  • Table 26 Global In Vivo Toxicology Market Outlook, By End User (2020-2028) ($MN)
  • Table 27 Global In Vivo Toxicology Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
  • Table 28 Global In Vivo Toxicology Market Outlook, By Contract Research Organizations (2020-2028) ($MN)
  • Table 29 Global In Vivo Toxicology Market Outlook, By Academic & Research Institutes (2020-2028) ($MN)
  • Table 30 Global In Vivo Toxicology Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.